Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Structure-based Discovery Of Potent Bcl-xl Inhibitors Through Rescaffolding.

Home
Structure-based Discovery Of Potent Bcl-xl Inhibitors Through Rescaffolding.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

'They're waiting for us to break before they listen': healthcare workers' perspectives on how to mitigate moral distress in British Columbia, Canada.

Primary health care research & development·2026

Same author

A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.

Leukemia·2026

Same author

Ebola: ignoring past lessons puts women at risk.

Lancet (London, England)·2026

Same author

Comparative assessment of RT-dPCR and RT-qPCR for RNA quantification in IgG mRNA-lipid nanoparticle bioanalysis.

Bioanalysis·2026

Same author

Trends and inequities in primary and emergency care use among older adults in British Columbia: an analysis across age, sex, income, and rurality (2018-2023).

International journal for equity in health·2026

Same author

Isolation of a single Serratia fonticola strain from interstage samples in a drinking water treatment plant: Genomic insights and floc-shielding effects during chlorination.

Ecotoxicology and environmental safety·2026

Same journal

Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases.

Journal of medicinal chemistry·2026

Same journal

Recent Advances in Targeting RNA Splicing Factors with Small Molecules.

Journal of medicinal chemistry·2026

Same journal

Structure-Guided Optimization of α-Conotoxins Yields Potent and Selective Inhibitors of the Human α6β4 nAChR for Nicotine Addiction.

Journal of medicinal chemistry·2026

Same journal

Antibody-Assisted Protection from Paraoxon and Nerve Agent Model Compounds.

Journal of medicinal chemistry·2026

Same journal

Photocage Prodrug Coupled with Injectable Hydrogel for Self-Amplified Photochemotherapy.

Journal of medicinal chemistry·2026

Same journal

GPX4-Targeting Phenolato Zr<sup>IV</sup> Complexes Induce Ferroptosis and Lysosome-Dependent Cell Death for Immunotherapy of Chemoresistant Cancer.

Journal of medicinal chemistry·2026

See all related articles

Related Experiment Video

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding.

Matyas Pal Timari^1,2, Attila Paczal¹, Andras Herner¹

¹Servier Research Institute of Medicinal Chemistry, Záhony utca 7, Budapest H-1031, Hungary.

Journal of Medicinal Chemistry

|June 12, 2026

View abstract on PubMed

Summary

This summary is machine-generated.

Researchers developed novel BCL-XL inhibitors targeting cancer

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Related Experiment Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Area of Science:

Oncology
Molecular Biology
Drug Discovery

Background:

Evasion of apoptosis is a key characteristic of cancer development.
Dysregulation of BCL-XL, a BCL-2 family protein, is implicated in various cancers.

Purpose of the Study:

To design and synthesize novel BCL-XL inhibitors.
To optimize inhibitors for high binding affinity and further modification.
To evaluate their therapeutic potential in cancer treatment.

Main Methods:

Chemical synthesis of novel mono- and bicyclic BCL-XL inhibitors.
Assessment of binding affinities and cellular potency in BCL-XL-dependent cell lines.
In vivo evaluation using xenograft tumor models.

Main Results:

Novel inhibitors with unique mono- and bicyclic cores were synthesized.
Lead compounds demonstrated picomolar binding affinities and potent cellular activity.
Significant tumor growth inhibition was observed in xenograft studies.

Conclusions:

The novel BCL-XL inhibitors show promise as therapeutic agents.
Targeting the intrinsic apoptotic pathway via BCL-XL inhibition is a viable cancer treatment strategy.